Predict your next investment

Venture Capital
claremontcreek.com

See what CB Insights has to offer

Investments

89

Portfolio Exits

15

Funds

3

About Claremont Creek Ventures

Claremont Creek Ventures is a venture capital firm based in Oakland, California. The firm works closely with local institutions such as UC Berkeley, UC Davis, and the Lawrence Livermore and Berkeley Laboratories.

Claremont Creek Ventures Headquarters Location

300 Frank H. Ogawa Plaza Suite 350

Oakland, California, 94612,

United States

510-740-5001

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Claremont Creek Ventures News

DNAnexus Completes $68 Million Financing

Feb 6, 2019

DNAnexus, Inc. , the leader in biomedical informatics and data management, today announced closing a $68 million financing. The funds were raised from existing investors, GV (formerly Google Ventures), Foresite Capital, TPG Biotech , WuXi NextCODE, and Claremont Creek Ventures, as well as debt and equity financing from Innovatus Capital Partners, LLC. “DNAnexus has changed how global biomedical research and development markets manage their data and infrastructures,” commented Claes Ekstrom, Managing Director at Innovatus. “We are excited to support DNAnexus’ ongoing mission to accelerate science and medical discoveries by democratizing access to data through a global network.” The financing supports the deployment of DNAnexus Apollo ™, an advanced platform for multi-omics and clinical data exploration, analysis, and discovery. The Apollo Platform uses the DNAnexus global network, providing secure and compliant infrastructure with access to tools and datasets within a collaborative environment . DNAnexus supports some of the largest human genome sequencing projects in the world, including NIH’s All of Us , St. Jude Cloud , AstraZeneca’s 2-million genome initiative , and the Regeneron-Geisinger collaboration . “The financing enables further development of our translational research solutions, as well as continued growth in genomics with cloud-based solutions for research, clinical diagnostics, and clinical trials,” said Richard Daly, Chief Executive Officer at DNAnexus. “The next wave of biomedical insights will be derived from cross-institutional collaborations that generate massive volumes of clinical and multi-omics data. We are proud of our work dedicated to improving how global research and development organizations leverage large biomedical datasets to develop and deliver precision medicine solutions.” About DNAnexus DNAnexus, the leader in biomedical informatics and data management, has created the global network for genomics and other biomedical data, operating in 33 countries including North America, Europe, China, Australia, South America, and Africa. The secure, scalable, and collaborative DNAnexus Platform helps thousands of researchers across a spectrum of industries – biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia – accelerate their genomics programs. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus. About Innovatus Capital Partners Innovatus adheres to an investment strategy that identifies disruptive and growth opportunities across multiple asset categories with a unifying theme of capital preservation, income generation, and upside optionality. The Firm has a dedicated team of life sciences investment professionals with deep experience in healthcare, including life sciences. Innovatus and its principals have significant experience providing debt financing to medical device, diagnostics, and biotechnology companies that address unmet medical needs, improve patient outcomes, and reduce overall healthcare expenditures. Further information can be found at innovatuscp.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20190206005088/en/ Media Contact:

Claremont Creek Ventures Investments

89 Investments

Claremont Creek Ventures has made 89 investments. Their latest investment was in Trove as part of their Series C on September 9, 2019.

CBI Logo

Claremont Creek Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/26/2019

Series C

Trove

$20M

No

3

2/6/2019

Series F - II

DNAnexus

$68M

No

3

2/15/2018

Series B

Trove

$12.57M

No

3

1/2/2018

Series F

Subscribe to see more

$99M

Subscribe to see more

10

3/15/2017

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/26/2019

2/6/2019

2/15/2018

1/2/2018

3/15/2017

Round

Series C

Series F - II

Series B

Series F

Unattributed

Company

Trove

DNAnexus

Trove

Subscribe to see more

Subscribe to see more

Amount

$20M

$68M

$12.57M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

3

3

10

10

Claremont Creek Ventures Portfolio Exits

15 Portfolio Exits

Claremont Creek Ventures has 15 portfolio exits. Their latest portfolio exit was Zipline Medical on December 31, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/31/2019

Acquired

$99M

1

8/19/2019

Acquired

$99M

2

6/13/2019

Acquired

$99M

1

6/26/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/7/2017

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/31/2019

8/19/2019

6/13/2019

6/26/2018

6/7/2017

Exit

Acquired

Acquired

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Claremont Creek Ventures Fund History

3 Fund Histories

Claremont Creek Ventures has 3 funds, including Claremont Creek Ventures Fund II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/2/2008

Claremont Creek Ventures Fund II LP

Early-Stage Venture Capital

Closed

$175M

1

11/18/2005

Claremont Creek Ventures Fund I LP

Subscribe to see more

Subscribe to see more

$99M

10

Claremont Creek Ventures Fund III LP

Subscribe to see more

Subscribe to see more

10

Closing Date

10/2/2008

11/18/2005

Fund

Claremont Creek Ventures Fund II LP

Claremont Creek Ventures Fund I LP

Claremont Creek Ventures Fund III LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

$175M

$99M

Sources

1

10

10

Claremont Creek Ventures Team

4 Team Members

Claremont Creek Ventures has 4 team members, including current Founder, Managing Director, Nathaniel Goldhaber.

Name

Work History

Title

Status

Nathaniel Goldhaber

CyberGold, Sun Microsystems, TopS Business Integrator, and Commonwealth of Pennsylvania

Founder, Managing Director

Current

John Steuart

Prolog Ventures, MyPoints, CyberGold, and Alafi Capital

Founder

Current

Randall Hawks

Horizon Ventures, WHEB, Identix, Qume, and Texas Instruments

Managing Director

Current

Greg Lahann

Alta Energy, ERP Power, and MK Global Ventures

Chief Financial Officer

Former

Name

Nathaniel Goldhaber

John Steuart

Randall Hawks

Greg Lahann

Work History

CyberGold, Sun Microsystems, TopS Business Integrator, and Commonwealth of Pennsylvania

Prolog Ventures, MyPoints, CyberGold, and Alafi Capital

Horizon Ventures, WHEB, Identix, Qume, and Texas Instruments

Alta Energy, ERP Power, and MK Global Ventures

Title

Founder, Managing Director

Founder

Managing Director

Chief Financial Officer

Status

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.